Literature DB >> 27502724

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

N Lawrence1, A Martin2, G Toner3, M Stockler2,4,5, L Buizen2, D Thomson6, V Gebski2, M Friedlander7, A Yeung2, N Wong2, H Gurney8, M Rosenthal9, N Singhal10, G Kichenadasse11, S Wong12, C Lewis7, P Vasey13, P Grimison4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27502724     DOI： 10.1093/annonc/mdw313

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  1 in total

1.  Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours.

Authors:  Nicola J Lawrence; Howard Chan; Guy Toner; Martin R Stockler; Andrew Martin; Sonia Yip; Nicole Wong; Annie Yeung; Danish Mazhar; Farzana Pashankar; Lindsay Frazier; Ray McDermott; Roderick Walker; Hsiang Tan; Ian D Davis; Peter Grimison
Journal:  BMC Cancer       Date:  2018-08-29       Impact factor: 4.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.